1. Home
  2. XOMAP vs CHUY Comparison

XOMAP vs CHUY Comparison

Compare XOMAP & CHUY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAP
  • CHUY
  • Stock Information
  • Founded
  • XOMAP N/A
  • CHUY 1982
  • Country
  • XOMAP United States
  • CHUY United States
  • Employees
  • XOMAP 13
  • CHUY N/A
  • Industry
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • CHUY Restaurants
  • Sector
  • XOMAP Health Care
  • CHUY Consumer Discretionary
  • Exchange
  • XOMAP Nasdaq
  • CHUY Nasdaq
  • Market Cap
  • XOMAP N/A
  • CHUY N/A
  • IPO Year
  • XOMAP N/A
  • CHUY 2012
  • Fundamental
  • Price
  • XOMAP $25.90
  • CHUY $23.99
  • Analyst Decision
  • XOMAP
  • CHUY Buy
  • Analyst Count
  • XOMAP 0
  • CHUY 8
  • Target Price
  • XOMAP N/A
  • CHUY $35.75
  • AVG Volume (30 Days)
  • XOMAP N/A
  • CHUY 163.7K
  • Earning Date
  • XOMAP N/A
  • CHUY 08-01-2024
  • Dividend Yield
  • XOMAP N/A
  • CHUY N/A
  • EPS Growth
  • XOMAP N/A
  • CHUY 33.86
  • EPS
  • XOMAP N/A
  • CHUY 1.70
  • Revenue
  • XOMAP N/A
  • CHUY $459,276,000.00
  • Revenue This Year
  • XOMAP N/A
  • CHUY $3.21
  • Revenue Next Year
  • XOMAP N/A
  • CHUY $10.19
  • P/E Ratio
  • XOMAP N/A
  • CHUY $14.01
  • Revenue Growth
  • XOMAP N/A
  • CHUY 5.77
  • 52 Week Low
  • XOMAP N/A
  • CHUY $22.52
  • 52 Week High
  • XOMAP N/A
  • CHUY $42.89
  • Technical
  • Relative Strength Index (RSI)
  • XOMAP 46.85
  • CHUY 31.59
  • Support Level
  • XOMAP $25.31
  • CHUY $22.52
  • Resistance Level
  • XOMAP $25.80
  • CHUY $24.09
  • Average True Range (ATR)
  • XOMAP 0.30
  • CHUY 0.60
  • MACD
  • XOMAP -0.03
  • CHUY -0.10
  • Stochastic Oscillator
  • XOMAP 20.01
  • CHUY 35.67

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: